30
CARDIOVASCULAR
hamburger

Quality Time Secured.

Tendyne™ TMVI is first-in-class technology that offers patients with symptomatic, significant mitral regurgitation (grade >3) a minimally invasive treatment option for valve replacement.

  • Most patients (99%) achieve complete MR elimination at 30 days, with sustained MR elimination in the majority at 1 and 2 years1
  • Technical success rate of 96%1,*
  • Clinically significant improvement in symptom and quality-of-life measures1

*Technical success per MVARC.

Distinct Design for Device Control and Flexibility

  • Specifically designed for the challenging mitral anatomy
  • Contoured, dual-frame design easily conforms to mitral annulus, supporting a secure seal
  • Fully repositionable and retrievable intraprocedurally for optimal valve placement
  • Array of valve sizes to address a wide range of annular dimensions
Tendyne mitral valve features

Learn more about Tendyne™ TMVI by visiting the Abbott Structural Heart website.

Ordering Information

Valve Product Specifications

 

MODEL Valve Number Catalog Number Device AP (mm) Device IC (mm) Device Perimeter (mm) EOA (cm2)
SP 33S TENDV-SP-33S 32.5 43.5 130 3.0
33M TENDV-SP-33M 32.5 46.5 136
33L TENDV-SP-33L 32.5 50.5 144
35M TENDV-SP-35M 34.5 48.5 144
37S TENDV-SP-37S 36.5 46.5 144
37L TENDV-SP-37L 36.5 52.5 156
39M TENDV-SP-39M 38.5 50.5 156
41S TENDV-SP-41S 40.5 47.5 154
LP 29S TENDV-LP-29S 29.0 42.5 119 2.2
29L TENDV-LP-29L 29.0 47.5 129
33S TENDV-LP-33S 32.5 43.5 130
35M TENDV-LP-35M 34.5 48.5 144
37M TENDV-LP-37M 36.5 49.5 150

Implantation and Retrieval System Product Specifications

 

Description Catalog Number Approximate Dimensions (cm)
Tendyne™ Loading System TENDV-LS 18 x 9 x 61
Tendyne™ Delivery System* TENDV-DS 6.5 x 7.5 x 89
Tendyne™ Pad Position System TENDV-PS 5 x 7.5 x 38
Tendyne™ Retrieval System* TENDV-RS 18 x 10 x 76
Tendyne 2 Lb. Weight TENDV-WT N/A
Tendyne Stand TENDV-ST N/A
Tendyne Stand Components TENDV-SC N/A
*Sheath ID for the delivery system and retrieval system is 36F.
References

1. Muller D, et al. Two-Year Outcomes of Tendyne Transcatheter Mitral Valve Implantation to Treat Symptomatic, Severe Mitral Regurgitation. Presented at PCR E-Course, June, 2020.

MAT-2002383 v3.0 | Item approved for Global OUS use only.

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

True
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.